The Novavax story: How a struggling company won $1.6 billion to make a coronavirus vaccine

Although the company, based in Gaithersburg, Maryland, had never brought a vaccine to market in its 33-year history, these experts were optimistic about its technology, which uses moth cells to pump out crucial molecules at a much faster rate than typical vaccines — a major advantage in a pandemic.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3h6zNM1
via IFTTT